Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data
Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data
Contenu indisponible. Consultez la source originale.
Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.